- 33. (Twice amended) The composition of claim 32, comprising said gene in combination with adriamycin, 5-fluorouracil, etoposide, camptothecin, actinomycin-D [actimomycin-D], mitomycin C, or cisplatin.
- (Amended) The method of claim 97, wherein said non-small cell lung carcinoma cell is a squamous [sqamous] carcinoma cell.

## REMARKS

The amendment to the specification is needed to correct a typographical error in the Specification as filed. Support for this amendment can be found in the inventors' Declaration previously filed with the U.S. Patent Office.

Claim 127 was cancelled because the claim, as previously amended, did not introduce any further limitations than the claim from which it depended. Claims 2, 33, and 98 were amended to correct misspellings. Claim 5 has been amended to clarify an inconsistency in the claim.

Applicants respectfully submit that these amendments does not introduce any new matter into the specification.

The Examiner is invited to contact the undersigned attorney at (512) 418-3081 with any questions, comments or suggestions relating to the referenced patent application.

Please date-stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Gina N. Shishima Reg. No. 45,104

Attorney for Applicant

FULBRIGHT & JAWORSKI 600 Congress Avenue Suite 1900 Austin, Texas 78701 (512) 418-3000

Date:

October 24, 2000